NORRIS MEDICINES LTD.

Norris Medicines Ltd has announced its 35th Annual General Meeting (AGM) for the Financial Year 2025-26. The meeting is scheduled for Tuesday, September 29, 2026, at 02:30 PM IST, and will be conducted via Video Conference/Other Audio-Visual Means (VC/OAVM). The company has also provided details for remote e-voting, with the cut-off date for eligibility being September 22, 2026. Remote e-voting will commence on September 26, 2026, and conclude on September 28, 2026. The Annual Report for FY 2025-26, along with the AGM notice, is available on the company's website, the BSE India website, and the Purva Sharegistry website.

Norris Medicines Ltd has filed its 35th Annual Report for the financial year 2025-26, as per SEBI regulations. The report, sent electronically to shareholders, is also available on the company's website. It includes the Board's Report, Secretarial Audit Report, Management Discussion and Analysis, financial statements (Balance Sheet, Profit & Loss, Cashflow), and auditor's report. The Annual General Meeting (AGM) is scheduled for September 29, 2026, to adopt the audited financial statements for the year ended March 31, 2026, and to re-appoint Mr. Praveen J. Bafna as Director. Additionally, a special resolution will be considered for the appointment of Mr. Vimal D. Shah as Managing Director.

Norris Medicines Ltd announced the outcome of its Board Meeting held on September 3, 2026. The board approved the Directors Report for the Financial Year ended 2025-2026, along with related annexures. Key decisions included approving the closure of the Register of Members and Share Transfer Books for the upcoming Annual General Meeting (AGM). The company also approved the cut-off date for electronic voting entitlements and the convening of the 35th AGM on September 29, 2026, to be held via Video Conferencing (VC) or Other Audio-Visual Means (OAVM). The 35th Annual Report, including the AGM notice, was also approved. Furthermore, the board appointed Mr. Hemant Shetye as the scrutinizer for the e-voting process and Purva Sharegistry (India) Pvt. Ltd. to facilitate e-voting at the AGM. Directors and the Company Secretary were authorized to conduct the AGM and manage related documentation.

Norris Medicines Limited announced the appointment of Mr. Vimal Dhirendra Shah (DIN: 01506655) as Managing Director for a term of three years, effective September 1, 2026, until August 31, 2029. This reappointment is subject to shareholder approval. Mr. Shah, a commerce graduate with over 15 years of business management experience, also serves on the Audit Committee and Stakeholders Relationship Committee. The company also reported its un-audited financial results for the quarter ended June 30, 2026, showing a net loss of ₹39.68 lakhs. The Board of Directors approved these results and the appointment during their meeting held on August 14, 2026.

Norris Medicines Limited announced its un-audited financial results for the quarter ended June 30, 2026. The Board of Directors also approved the appointment of Mr. Vimal Dhirendra Shah as Managing Director for a term of three years, effective September 1, 2026, subject to shareholder approval. The company is arranging to publish the financial results in newspapers as per SEBI regulations. The board meeting commenced at 3:00 PM and concluded at 4:00 PM.

Norris Medicines Limited held a Board Meeting on August 14, 2026, to approve the un-audited financial results for the quarter ended June 30, 2026 (Q1 FY27). The Board also approved the appointment of Mr. Vimal Dhirendra Shah as Managing Director for a three-year term, effective September 1, 2026, subject to shareholder approval. The financial results were reviewed by statutory auditors and will be published in newspapers.

Norris Medicines Ltd has announced that its Board of Directors will convene on August 14, 2026, to consider and approve the unaudited financial results for the quarter ending June 30, 2026. The meeting will take place at the company's registered office in Ankleshwar, Gujarat. Additionally, the company has reminded stakeholders that the trading window for dealing in its securities remains closed from July 1, 2026, and will reopen 48 hours after the declaration of the financial results.

Norris Medicines Ltd announced the appointment of Mr. Iqubal Ismail Patel as Chief Financial Officer (CFO) and Key Managerial Personnel (KMP) of the company. The decision was approved by the Board of Directors in a meeting held on July 30, 2026, following recommendations from the Audit Committee and the Nomination and Remuneration Committee. Mr. Patel has over 11 years of experience with the company in finance, accounts, taxation, budgeting, financial planning, and corporate management. He is not related to any existing Directors or KMPs. His appointment is effective from July 30, 2026, with terms and remuneration to be mutually agreed upon.

Norris Medicines Ltd announced the appointment of Mr. Iqubal Ismail Patel as the new Chief Financial Officer (CFO) and Key Managerial Personnel (KMP) of the company, effective July 30, 2026. The decision was approved by the Board of Directors following recommendations from the Audit Committee and the Nomination and Remuneration Committee. Mr. Patel brings over 11 years of experience in finance, accounts, taxation, budgeting, financial planning, and corporate management to the role. He is not related to any existing Directors or KMPs. The board meeting commenced at 5:00 PM and concluded at 5:30 PM.

Norris Medicines Ltd has announced the closure of its trading window for designated persons, including promoters, directors, auditors, and key managerial personnel, effective July 1, 2026. This closure is in accordance with the company's code of conduct for prohibiting insider trading, aligned with SEBI regulations. The trading window will reopen 48 hours after the public declaration of the un-audited financial results for the quarter ending June 30, 2026. The specific date for the board meeting to approve these results will be communicated separately. During the closure, all designated individuals are prohibited from trading in the company's securities.